Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 31869 | 117 | 35.2 | 92% |
Classes in level above (level 2) |
| ID, lev. above |
Publications | Label for level above |
|---|---|---|
| 1455 | 7277 | MESOTHELIOMA//MALIGNANT MESOTHELIOMA//MALIGNANT PLEURAL MESOTHELIOMA |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | BAP1 | Author keyword | 15 | 41% | 24% | 28 |
| 2 | BRCA1 ASSOCIATED PROTEIN 1 | Author keyword | 6 | 100% | 3% | 4 |
| 3 | SETD2 | Author keyword | 4 | 46% | 5% | 6 |
| 4 | PBRM1 | Author keyword | 2 | 33% | 3% | 4 |
| 5 | BAP1 CANCER SYNDROME | Author keyword | 1 | 100% | 2% | 2 |
| 6 | BAP1 PROTEIN | Author keyword | 1 | 100% | 2% | 2 |
| 7 | H2AK119UB1 | Author keyword | 1 | 100% | 2% | 2 |
| 8 | HUASHAN UROL | Address | 1 | 100% | 2% | 2 |
| 9 | BRCA ASSOCIATED PROTEIN 1 | Author keyword | 1 | 50% | 1% | 1 |
| 10 | CLIN SCI H4 | Address | 1 | 50% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | BAP1 | 15 | 41% | 24% | 28 | Search BAP1 | Search BAP1 |
| 2 | BRCA1 ASSOCIATED PROTEIN 1 | 6 | 100% | 3% | 4 | Search BRCA1+ASSOCIATED+PROTEIN+1 | Search BRCA1+ASSOCIATED+PROTEIN+1 |
| 3 | SETD2 | 4 | 46% | 5% | 6 | Search SETD2 | Search SETD2 |
| 4 | PBRM1 | 2 | 33% | 3% | 4 | Search PBRM1 | Search PBRM1 |
| 5 | BAP1 CANCER SYNDROME | 1 | 100% | 2% | 2 | Search BAP1+CANCER+SYNDROME | Search BAP1+CANCER+SYNDROME |
| 6 | BAP1 PROTEIN | 1 | 100% | 2% | 2 | Search BAP1+PROTEIN | Search BAP1+PROTEIN |
| 7 | H2AK119UB1 | 1 | 100% | 2% | 2 | Search H2AK119UB1 | Search H2AK119UB1 |
| 8 | BRCA ASSOCIATED PROTEIN 1 | 1 | 50% | 1% | 1 | Search BRCA+ASSOCIATED+PROTEIN+1 | Search BRCA+ASSOCIATED+PROTEIN+1 |
| 9 | COMBINED NEVI | 1 | 50% | 1% | 1 | Search COMBINED+NEVI | Search COMBINED+NEVI |
| 10 | DEVELOPMENTAL SYNDROME | 1 | 50% | 1% | 1 | Search DEVELOPMENTAL+SYNDROME | Search DEVELOPMENTAL+SYNDROME |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | UBIQUITIN HYDROLASE | 36 | 77% | 21% | 24 |
| 2 | BRCA1 ASSOCIATED PROTEIN 1 | 36 | 71% | 25% | 29 |
| 3 | DEUBIQUITINASE BAP1 | 6 | 71% | 4% | 5 |
| 4 | MUTATIONS PREDISPOSE | 6 | 100% | 3% | 4 |
| 5 | BAP1 | 5 | 28% | 13% | 15 |
| 6 | PBRM1 | 4 | 50% | 5% | 6 |
| 7 | PREDISPOSE | 3 | 12% | 21% | 24 |
| 8 | PATHOLOGICAL IMPACT | 2 | 67% | 2% | 2 |
| 9 | SETD2 | 2 | 67% | 2% | 2 |
| 10 | TRANSCRIPTION FACTOR FOXK2 | 2 | 67% | 2% | 2 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology | 2015 | 2 | 52 | 23% |
| Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma | 2015 | 3 | 20 | 15% |
| Tumours associated with BAP1 mutations | 2013 | 25 | 77 | 30% |
| The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics | 2013 | 23 | 43 | 30% |
| Cooperation and Antagonism among Cancer Genes: The Renal Cancer Paradigm | 2013 | 7 | 36 | 39% |
| BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies | 2015 | 0 | 59 | 47% |
| PBRM1 and BAP1 as Novel Targets for Renal Cell Carcinoma | 2013 | 8 | 100 | 25% |
| Developmental Disease and Cancer: Biological and Clinical Overlaps | 2013 | 4 | 41 | 12% |
| Impact of NGS in the medical sciences: Genetic syndromes with an increased risk of developing cancer as an example of the use of new technologies | 2014 | 1 | 12 | 8% |
| Stratification of clear cell renal cell carcinoma by signaling pathway analysis | 2014 | 2 | 46 | 7% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | HUASHAN UROL | 1 | 100% | 1.7% | 2 |
| 2 | CLIN SCI H4 | 1 | 50% | 0.9% | 1 |
| 3 | EXPERT CANC RA INCA PREDIR | 1 | 50% | 0.9% | 1 |
| 4 | HOP UNIV PARIS SUD BICETRE | 1 | 50% | 0.9% | 1 |
| 5 | HUMAN ONCOL PATHOGENESIS PROGRAM LEUKEMIA SER | 1 | 50% | 0.9% | 1 |
| 6 | INSERM UMR1069 | 1 | 50% | 0.9% | 1 |
| 7 | KIDNEY KEYSTONE PROGRAM | 1 | 50% | 0.9% | 1 |
| 8 | ONCOGENET SERV | 1 | 50% | 0.9% | 1 |
| 9 | BREAST SURG BURNS UNIT | 0 | 33% | 0.9% | 1 |
| 10 | EYE CANC GRP | 0 | 33% | 0.9% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000210969 | MEYERSON PHENOMENON//MEYERSONS NEVUS//HALO DERMATITIS |
| 2 | 0.0000189965 | EVOLUT CANC//PETOS PARADOX//TRANSLAT CANC THER EUT |
| 3 | 0.0000156513 | USP22//UCH L1//DEUBIQUITINATING ENZYME |
| 4 | 0.0000150208 | UVEAL MELANOMA//CHOROIDAL MELANOMA//MONOSOMY 3 |
| 5 | 0.0000135513 | MESOTHELIOMA//MALIGNANT PLEURAL MESOTHELIOMA//EXTRAPLEURAL PNEUMONECTOMY |
| 6 | 0.0000129740 | CDKN2A//MC1R//MELANOCORTIN 1 RECEPTOR |
| 7 | 0.0000118953 | HEMANGIOBLASTOMAS//VON HIPPEL LINDAU DISEASE//HAEMANGIOBLASTOMA |
| 8 | 0.0000116914 | SPITZ NEVUS//DESMOPLASTIC MELANOMA//MALIGNANT BLUE NEVUS |
| 9 | 0.0000091126 | RENAL ONCOCYTOMA//CHROMOPHOBE RENAL CELL CARCINOMA//COLLECTING DUCT CARCINOMA |
| 10 | 0.0000087301 | SWI SNF//BRG1//ISWI |